Author's reply
Dr Vivekanandan makes a number of points in his letter. He is of the view that cardiac marker testing is required in only a minority of patients. Experience at the Mayday hospital has shown that only 10% of patients present with ST segment acute coronary syndromes. 4% have equivocal ECG ®ndings, 9% have high risk unstable angina (UA) missed by current testing strategies, 73% have either low risk UA or nonischaemic chest pain and 4% are classi®ed as acute myocardial infarction (AMI) (on the basis of clinical and current cardiac enzyme strategies) who actually have not had an AMI but in fact have elevation of creatine kinase of musculoskeletal origin. Cardiac marker results are therefore required in 90% of cases to con®rm or exclude diagnosis. The routine measurement of cardiac troponins for this purpose is endorsed by European and American cardiac societies. 1, 2 The only test which currently provides a truly cardiospeci®c diagnosis is measurement of cardiac troponin (cTn), either cardiac troponin T (cTnT) or cardiac troponin I (cTnI) (although some methods for cTnI are better than others).
3±7 Measurement of CK, CK-MB or CK-MB/CK ratio is redundant for this purpose. To detect cardiac damage in patients undergoing non-cardiac surgery, measurement of cTnT or cTnI 12±24 h from the suspected index event is required.
8 Any detectable troponin above the detection limit of the assay indicates cardiac damage, with the extent of damage proportional to the magnitude of elevation.
9,10 In cardiac surgery, the perfect cardiac surgeon causes no troponin release. This is illustrated in minimally invasive cardiac surgery (MIDCAB), in which troponin release does not occur.
11 Perioperative AMI is associated with greater rises of cTn 12 and there is positive correlation between cTn release and cross clamp time. 13 For a comprehensive review on the subject I recommend the recent book edited by Alan Wu. 
Thyroid function tests in acutely ill patients
Lamb and Martin 1 found six new cases of hypothyroidism among 129 consecutive inpatients (i.e. a prevalence 4´6%) and they conclude that thyroid function tests (TFTs) are thus clinically justi®ed in many unwell patients. Their conclusion, however, is not supported by their ®ndings.
They considered requests to be justi®ed if the clinical history increased the probability of thyroid disease and/or if there were common symptoms and signs of thyroid disease. However, most of the symptoms and signs they listed are not speci®c to thyroid disease and are often present in acutely ill patients. Indeed, they comment in the discussion that`abnormal results rarely re¯ected the clinical indication'. Moreover, there was no difference in the number of thyroid cases picked up in the clinically unjusti®ed group compared with the clinically justi®ed group. In a systemic review, Attia et al. 2 were unable to ®nd any articles which tested the usefulness of clinical signs and symptoms for the diagnosis of thyroid disease in acutely ill patients. Others have found that even in inpatients with atrial ®brillation, the prevalence of thyroid disease was similar to that in the general population. 3 The prevalence of symptomatic thyroid disease in the general population is 1±2% and the prevalence of subclinical disease is 2±6%. The prevalence of undiagnosed thyroid disease of 4´6% in this study was therefore similar to that in the general population.
The gold standard for differentiating the effects of acute illness and/or drugs on TFTs and true thyroid disease remains a detailed follow-up after discharge. In two of their six new' cases, thyroxine replacement therapy was commenced before discharge (one patient had a thyroid stimulating hormone (TSH) concentration of 5´1 mU/L and the other a TSH of 8´1 mU/L) and therefore the possibility that their abnormal TFTs may have been due to non-thyroidal illness cannot be excluded with certainty.
Based on current evidence, requesting TFTs on inpatients may be useful in some circumstances, namely if the reason for admission is thought to be due to a thyroid disorder and in patients with known thyroid disease. The ®ndings presented in this paper provide no scienti®c evidence to the contrary. Requesting TFTs on all acutely ill patients, as suggested by Lamb and Martin, is at best inappropriate and at worst misleading.
Chemical Pathologists and Clinical Biochemists should not only ensure the optimal use of ®nite laboratory resources but should also minimize unjusti®ed and often uninterpretable TFTs carried out on acutely ill patients. We read with interest the paper by Lamb and Martin. 1 However, we would suggest a different interpretation of their ®ndings.
They maintain that in 87 of the 129 patients, thyroid function tests (TFTs) were justi®ed on clinical grounds. However, from Fig. 1 it is clear that only 156 symptoms/signs were noted to justify requesting TFTs in the 89 patients, i.e. less than two symptoms/signs per patient. In a study of 500 patients by White and Walmsley, 2 only two of 442 patients with one and/or two symptoms/signs suggestive of thyroid dysfunction were eventually diagnosed as suffering from thyroid disease. It would be interesting to know how many of the 89 patients considered by Lamb and Martin had one and two symptoms/ signs, respectively.
In a study by Small and colleagues, TFTs were measured in 630 consecutive acute medical admissions.
3`A bnormal' TFTs were noted in 125 patients. This ®nding is not signi®cantly different from that of Lamb and Martin, who found 28 abnormal TFTs in the 129 patients they studied. This suggests that practice in the Kent and Canterbury Hospital is approaching that of routine screening, which few would advocate.
It is true that thyroid function tests are often justi®ed. However, the data provided by Lamb and Martin, we believe, supports the view that TFTs are increasingly being requested inappropriately.
E BELL D STJ O'REILLY
Department of Clinical Biochemistry, Royal In®rmary, Glasgow G4 0SF, UK non-speci®c, it is incumbent on an admitting physician to consider a thyroid disorder in the differential diagnosis of patients presenting with such features. The study of White and Walmsley 2 is not directly comparable to our own, since they included both inpatients and outpatients and excluded patients with known pre-existing thyroid disease. Additionally, the range of symptoms and signs they recorded included many with weaker associations to thyroid disease (e.g. recent myocardial infarction, hypertension, asthma and pneumonia) than those used in our study. Amongst our six con®rmed new cases of hypothyroidism, the total symptom/sign score was nine (i.e. only one or two symptoms/signs per patient), but this rises to 17 using the White and Walmsley system. To use the example Vallance and Labib have quoted, it is interesting that the prevalence of thyroid disease amongst patients with atrial ®brillation is similar to that in the general population. Nevertheless, atrial ®brilla-tion is a recognized consequence of thyroid disease and hyperthyroidism will feature amongst the differential causes of this condition in most standard medical textbooks (e.g.
Oxford Handbook of Clinical Medicine).
It would be remiss of a physician not to request a TFT in this situation, and surely wrong of any laboratory to argue against its justi®ca-tion?
We have at no point advocated`requesting TFTs on all acutely ill patients' as stated by Vallance and Labib, and the practice in our hospital is clearly not that of`routine' unselective screening, in the sense intended by Bell and O'Reilly. Our hospital has approximately 800 acute medical admissions each month. During the month of our study, 143 of these patients (129 of which we were able to audit) had TFTs requested, the majority of which we found to be clinically justi®ed. Amongst these, we identi®ed a signi®cant number of patients with thyroid pathology requiring treatment or follow-up. In our opinion, it is redundant for laboratory pathologists to continue to simply state that such tests are misleading. Rather, they should focus their energies on assisting clinicians in understanding the important information produced by such results.
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